Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

By the numbers bringing new drugs for allergic/hypersensitivity diseases to the market

By the numbers bringing new drugs for allergic/hypersensitivity diseases to the market CE: Alpana; ACI/150313; Total nos of Pages: 2; ACI 150313 EDITORIAL URRENT By the numbers: bringing new drugs for allergic/ PINION hypersensitivity diseases to the market a,b c,d Pascal Demoly and Henry Milgrom Allergic/hypersensitivity diseases comprise several One demand placed on clinical research is that clinical presentations, including asthma, rhinitis, study results be not merely significant (statistically) anaphylaxis, drug, food, and insect hypersensitivity, but also meaningful (clinically). Without the right eczema, urticaria and angioedema. The impact of analytical methods, more data just give us a more allergic/hypersensitivity diseases, both mild and precise estimate of the wrong subject. Although stat- severe, is well known worldwide, affecting the quality istical significance examines whether the findings are of life of patients and their careers and adding to the likely to be due to chance, the effect size characterizes world’s health expenditures. New medications for the the magnitude of an effect or the strength of a relation- most prevalent allergic/hypersensitivity diseases lin- ship. Both are essential to understand the findings of ger in the pharma industry pipeline. Development of clinical trials. When a large population sample is these new medications is often planned hand in hand studied, unless there is no effect at http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Opinion in Allergy and Clinical Immunology Wolters Kluwer Health

By the numbers bringing new drugs for allergic/hypersensitivity diseases to the market

Milgrom, Henry
Current Opinion in Allergy and Clinical Immunology , Volume Publish Ahead of Print – Apr 1, 2015
Download PDF
2 pages

Loading next page...
 
/lp/wolters-kluwer-health/by-the-numbers-bringing-new-drugs-for-allergic-sol-hypersensitivity-d8aNiqXTAi

References (14)

Copyright
Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
ISSN
1528-4050
eISSN
1473-6322
DOI
10.1097/ACI.0000000000000170
pmid
25899699
Publisher site
See Article on Publisher Site

Abstract

CE: Alpana; ACI/150313; Total nos of Pages: 2; ACI 150313 EDITORIAL URRENT By the numbers: bringing new drugs for allergic/ PINION hypersensitivity diseases to the market a,b c,d Pascal Demoly and Henry Milgrom Allergic/hypersensitivity diseases comprise several One demand placed on clinical research is that clinical presentations, including asthma, rhinitis, study results be not merely significant (statistically) anaphylaxis, drug, food, and insect hypersensitivity, but also meaningful (clinically). Without the right eczema, urticaria and angioedema. The impact of analytical methods, more data just give us a more allergic/hypersensitivity diseases, both mild and precise estimate of the wrong subject. Although stat- severe, is well known worldwide, affecting the quality istical significance examines whether the findings are of life of patients and their careers and adding to the likely to be due to chance, the effect size characterizes world’s health expenditures. New medications for the the magnitude of an effect or the strength of a relation- most prevalent allergic/hypersensitivity diseases lin- ship. Both are essential to understand the findings of ger in the pharma industry pipeline. Development of clinical trials. When a large population sample is these new medications is often planned hand in hand studied, unless there is no effect at

Journal

Current Opinion in Allergy and Clinical Immunology – Wolters Kluwer Health

Published: Apr 1, 2015

There are no references for this article.